Annalise.ai Builds Momentum in U.S. Market with Seven Additional FDA-Cleared Findings for Imaging Triage and Notification
SYDNEY, April 12, 2023 /PRNewswire/ -- Annalise.ai, the global radiology AI company, announced today that it has received FDA 510(k) clearances covering an additional seven findings as part of the company's innovative AI-assisted triage and notification (CADt) solutions. The clearances, including a suite of time-sensitive stroke findings and an expansion of findings for chest X-ray, build on Annalise's momentum and growth strategy in the U.S. market.
- Annalise.ai has received new 510(k) FDA clearances for seven additional time-critical findings in its chest X-ray (CXR) and non-contrast head CT triage and notification portfolio.
- The latest 510(k) FDA clearances build on Annalise.ai's momentum for expanding into the U.S. market, bringing the total number of U.S.-available findings for its triage and notification products to nine.
- SYDNEY, April 12, 2023 /PRNewswire/ -- Annalise.ai, the global radiology AI company, announced today that it has received FDA 510(k) clearances covering an additional seven findings as part of the company's innovative AI-assisted triage and notification (CADt) solutions.
- The clearances, including a suite of time-sensitive stroke findings and an expansion of findings for chest X-ray, build on Annalise's momentum and growth strategy in the U.S. market.